- Home
- ALL vs TAK Comparison
ALL vs TAK Comparison
Compare ALL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALL
- TAK
- Stock Information
- Founded
- ALL 1931
- TAK 1781
- Country
- ALL United States
- TAK Japan
- Employees
- ALL N/A
- TAK N/A
- Industry
- ALL Property-Casualty Insurers
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- ALL Finance
- TAK Health Care
- Exchange
- ALL Nasdaq
- TAK Nasdaq
- Market Cap
- ALL 53.1B
- TAK 47.3B
- IPO Year
- ALL 1993
- TAK N/A
- Fundamental
- Price
- ALL $200.40
- TAK $15.10
- Analyst Decision
- ALL Buy
- TAK
- Analyst Count
- ALL 14
- TAK 0
- Target Price
- ALL $219.23
- TAK N/A
- AVG Volume (30 Days)
- ALL 1.2M
- TAK 3.1M
- Earning Date
- ALL 10-29-2025
- TAK 10-30-2025
- Dividend Yield
- ALL 2.00%
- TAK 3.60%
- EPS Growth
- ALL 93.10
- TAK N/A
- EPS
- ALL 21.24
- TAK 0.59
- Revenue
- ALL $66,218,000,000.00
- TAK $31,053,301,865.00
- Revenue This Year
- ALL N/A
- TAK $0.40
- Revenue Next Year
- ALL $7.34
- TAK $0.83
- P/E Ratio
- ALL $9.44
- TAK $25.54
- Revenue Growth
- ALL 9.81
- TAK 1.52
- 52 Week Low
- ALL $176.00
- TAK $12.80
- 52 Week High
- ALL $214.76
- TAK $15.69
- Technical
- Relative Strength Index (RSI)
- ALL 45.24
- TAK 51.61
- Support Level
- ALL $198.58
- TAK $14.87
- Resistance Level
- ALL $202.76
- TAK $15.38
- Average True Range (ATR)
- ALL 2.81
- TAK 0.19
- MACD
- ALL -0.74
- TAK -0.01
- Stochastic Oscillator
- ALL 22.94
- TAK 35.16
About ALL Allstate Corporation (The)
Allstate is one of the largest US property-casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 6,000 exclusive agents.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.